

Orexin Receptor Type 1 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/O84490D4C8FDEN.html>

Date: October 2020

Pages: 86

Price: US\$ 3,500.00 (Single User License)

ID: O84490D4C8FDEN

Abstracts

Orexin Receptor Type 1 - Pipeline Review, H2 2020

SUMMARY

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 15 molecules. The latest report Orexin Receptor Type 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 3, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Binge Eating Disorder, Insomnia, Nicotine Addiction, Addiction, Alcohol Addiction, Obstructive Sleep Apnea, Opium (Opioid) Addiction, Anxiety Disorders, Dementia Associated With Alzheimer's Disease, Drug Addiction, Major Depressive Disorder, Narcolepsy, Panic Disorders, Parkinson's Disease, Pathological Gambling, Sleep Disorders and Smoking Cessation.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies
Involved in Therapeutics Development

Chronos Therapeutics Ltd

Eisai Co Ltd

Eolas Therapeutics Inc

Idorsia Pharmaceutical Ltd

Indivior Plc

Inexia Ltd

Johnson & Johnson

OXonium Therapeutics

Sosei Heptares

Taisho Pharmaceutical Holdings Co Ltd

Yangtze River Pharmaceutical Group

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles
ACT-539313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-010018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EORA-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INDV-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3215 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize HCRTR1 for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-142 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YZJ-1139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones

Featured News & Press Releases

Aug 28, 2020: Eisai presents new analyses from phase 3 studies of DAYVIGO (lemborexant) CIV for the treatment of insomnia in adult patients at Virtual SLEEP 2020

Aug 28, 2020: Daridorexant Phase 3 results in insomnia presented at SLEEP 2020

Aug 25, 2020: Eisai to present latest data of lemborexant at 34th Annual Sleep Meeting (SLEEP 2020)

Aug 13, 2020: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020

Aug 06, 2020: Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia - preparation for a local registration program advancing

Jul 22, 2020: Eisai to present latest data on Lemborexant at the Alzheimer's Association International Conference (AAIC) 2020

Jul 08, 2020: New drug application for in-house developed new anti-insomnia drug Dayvigo accepted in Hong Kong

Jul 06, 2020: Idorsia announces positive results in the second Phase 3 study of

daridorexant

Jul 06, 2020: Eisai to launch in-house developed new anti insomnia drug DAYVIGO Lemborexant with indication for insomnia in Japan

Jun 01, 2020: Eisai launches new insomnia drug dayvigo (lemborexant) CIV in the United States as a treatment option for adults with insomnia

Apr 21, 2020: Idorsia's insomnia drug daridorexant passes Phase III study

Jan 23, 2020: Eisai: Dayvigo (Lemborexant) approved for treatment of insomnia in Japan

Dec 27, 2019: Pivotal phase 3 study of DAYVIGO (lemborexant) for the treatment of insomnia disorder published in JAMA network open

Dec 23, 2019: U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for treatment of insomnia in adult patients

Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer's Disease (CTAD) conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Chronos Therapeutics Ltd, H2 2020

Pipeline by Eisai Co Ltd, H2 2020

Pipeline by Eolas Therapeutics Inc, H2 2020

Pipeline by Idorsia Pharmaceutical Ltd, H2 2020

Pipeline by Indivior Plc, H2 2020

Pipeline by Inexia Ltd, H2 2020

Pipeline by Johnson & Johnson, H2 2020

Pipeline by OXonium Therapeutics, H2 2020

Pipeline by Sosei Heptares, H2 2020

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2020

Pipeline by Yangtze River Pharmaceutical Group, H2 2020

Dormant Projects, H2 2020

Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Orexin Receptor Type 1 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/O84490D4C8FDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O84490D4C8FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970